This national registry-based observational study, conducted using data from the Third China National Stroke Registry (CNSR-III), compared the effectiveness and safety of atorvastatin versus rosuvastatin in 3322 adult patients (aged ≥18 years) with ischemic stroke or transient ischemic attack (TIA) who initiated either statin within 7 days of symptom onset, from August 2015 to March 2018. Eligible patients had a pre-stroke modified Rankin Scale (mRS) score of 0, indicating no disability. Of these, 2605 initiated atorvastatin, and 717 initiated rosuvastatin. The primary outcome was ideal, defined as an mRS score of 0 (no symptoms) at 3 months. Secondary outcomes included ideal outcomes at discharge, 6 months, and 12 months, as well as 12-month rates of stroke recurrence, all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events (MACE).
Mitochondrial dysfunction and oxidative stress, triggered by angiotensin II (Ang II) overactivation, are key drivers of cardiovascular disease (CVD) progression. This study compares the protective effects of nebivolol, a third-generation β1-adrenergic blocker, and metoprolol, a second-generation β1-adrenergic blocker, on Ang II-induced mitochondrial impairment in H9c2 cardiomyoblasts.
This study investigated the association between novel triglyceride- and triglyceride-glucose-derived obesity indices and hypertension (HTN) prevalence in nonobese adults, utilizing data from 12,717 participants in the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2020, representing approximately 119 million U.S. adults. The prevalence of HTN was 49.74% overall, with 53.45% in men.
Low-dose aspirin is often used to prevent superimposed preeclampsia in women with chronic hypertension, but its effectiveness remains limited. Factors such as dosage, timing of therapy initiation, timing of ingestion, and adherence may contribute to this reduced efficacy, yet these aspects are underexplored and yield conflicting results. Understanding the interplay of these factors and the underlying pathogenesis is critical to optimizing aspirin therapy.
Diffuse interstitial fibrosis is a key contributor to adverse outcomes in hypertensive heart disease and may be reversible. Sacubitril/valsartan, a combined angiotensin receptor- neprilysin inhibitor, may offer superior anti-fibrotic effects compared to valsartan alone. The REVERSE-LVH phase 2 open-label trial (clinicaltrials.gov NCT: 03553810), funded by the National Medical Research Council of Singapore, investigated the myocardial benefits of sacubitril/valsartan in patients with essential hypertension and left ventricular hypertrophy (LVH).
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists have individually improved outcomes in heart failure with preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF). However, the efficacy and safety of combining these agents remain untested in randomized trials, necessitating dedicated studies to evaluate potential synergistic benefits.
